Benzinga | Jan 5, 2022 09:27AM EST

Mizuho Maintains Buy on AbbVie, Raises Price Target to $154

Mizuho analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $132 to $154.